A range of SCD inhibitors is now available (e.g., A939572, SSI-4, g-PPT, MF-438), and most of these have been shown in preclinical models to produce stronger anti-tumor effects when combined with chemotherapy and targeted therapies [262–265]. Here, SCD is linked to neoplasm.